N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1 A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)
Epidermal Nevus Syndrome
Primary: The Participant Will Achieve Normal Age-adjusted Phosphorous Levels as Tested by Fasting Serum Lab Values — 0.8; 1.2; 1.3; 1.1 mg/dl
Phase 2 N=3 Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Netherton Syndrome
Primary: Blood Pimecrolimus Levels — 0; 0; 0.312; 1.260 ng/mL
Phase 2 N=24 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Neurofibromatosis 1
Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 3 N=174 Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Basal Cell Nevus Syndrome
Primary: Number of New BCCs Per Participant — 2.84; 4.03 New basal cell carcinomas
N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 2 N=14 Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Pediatric Cancer · CNS Tumor, Childhood · Skin Inflammation
Primary: Rate of Cutaneous Reaction — 7 Participants
Phase 2 N=19 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Primary: Percent of Participants With a 20% or More Change in Target Tumor Volume — 0; 8; 11; 0 Participants
Phase 2 N=11 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Phase 2 N=7 Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds
Phase 2 N=46 RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Dropout — 3; 2; 5; 2 Participants
Phase 2 N=25 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…
Phase 2 N=6 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Phase 2 N=45 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Phase 2 N=199 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Cutaneous Neurofibroma · Neurofibromatosis 1
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 35; 36; 49 Participants
Phase 2 N=10 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
N/A N=58 Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
Lesion Skin · Seborrheic Keratosis
Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance
Phase 2 N=48 NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Neurofibromatosis 1 · Cutaneous Neurofibroma
Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…
Phase 2 N=20 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…
N/A N=72 Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Skin Lesion · Skin Abnormalities · Sebaceous Hyperplasia
Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions
Phase 3 N=20 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Phase 2 N=86 Study of PEG-Intron for Plexiform Neurofibromas
Plexiform Neurofibroma
Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants
Phase 2 N=9 Medical Treatment of "High-Risk" Neurofibromas
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Phase 2 N=21 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Phase 2 N=12 A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Sjögren-Larsson Syndrome
Primary: Number of Participants Experiencing a Serious Adverse Event (SAE). — 0; 0 Participants
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…